DOLAUT GOLA COLLUT 150ML 0.25%

DOLAUT GOLA 0.25% COLLUTORIA

active ingredients

100 ml of collutory contain: Flurbiprofen 250 mg Excipients with known effects: propilenglycol, ethanol, hydrogenated castor oil-40-polyxyethylene. For the full list of excipients, see paragraph 6.1

Excellent

Propilenglycol, ethanol (96%), chlorhexidine digluconate solution, hydrogenated castor oil-40-polyxyethylene, sodium hydroxide, sodium saccharin, mint aroma, blue patent V (E 131), chinoline yellow (E 104), purified water.

Therapeutic indications

Symptomatic treatment of irritative-inflammatory states also associated with pain of the oropharyngeal cable (e.g. gums, stomatitis, pharyngitis), also as a result of conservative or extractive dentaria therapy.

Contraindications

Flurbiprofen is contraindicated in patients with known hypersensitivity (asthma, hives or allergic type) towards flurbiprofen or any of the excipients listed in paragraph 6.1., and towards aspirin or other NSAIDs. Third quarter of pregnancy. Flurbiprofene is not recommended during feeding. In patients who are suffering from peptic ulcer or have been affected in the past.

Population

The recommended dose is 2 or 3 rinses or gargles per day with 10 ml (1 scoop) of collutory. It can be diluted in water.

Conservation

This medicine does not require any special precaution for conservation

Warnings

At the recommended doses the possible swallowing of Dolaut gorge does not entail any harm to the patient as such doses are largely lower than those of the single posology of the product via systemic. The use of flurbiprofene collutory, especially if prolonged, can give rise to phenomena of sensitization or local irritation; in such cases it is necessary to stop the treatment and consult the doctor to establish, if necessary, suitable therapy. Do not use for protracted treatments. After short periods of treatment without appreciable results consult your doctor. In patients with kidney, heart or liver failure, the medicine must be used with caution. It is recommended not to associate the medicine with the NSAIDs. Important information about excipients This medicine contains 2000 mg of glycol propylene in 10 ml (1 scoop). It can cause skin irritation. This medicine contains 816.8 mg of alcohol (ethanol 96%) in 10 ml (1 scoop). It can cause burning sensation on the damaged skin. This medicine contains hydrogenated castor oil-40-polyxyethylene. It can cause reactions on the localized skin.

Interactions

Interactions with other medicines or other types have not been reported at recommended doses. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. In addition, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. In any case, please inform your doctor if you are taking other medicines.

Effects

The use of Dolaut gorge 0.25% Collutory, especially if prolonged, can give rise to phenomena of sensitization or local irritation; in such cases it is necessary to stop the treatment and to establish, if necessary, suitable therapy. The following undesirable effects were reported, particularly after the administration of systemic formulations: Emolinfopoietic system pathologies Trombocytopenia, aplastic anemia and agranulocytosis. Immune system disorders Anaphylaxis, angioedema, allergic reaction. Diseases of the nervous system Capogiri, cerebrovascular accidents, visual disorders, optic neuritis, migraine, paresthesia, depression, confusion, hallucination, dizziness, malaise, fatigue and drowsiness. Ear and labyrinth pathologies Tinnitus. Respiratory, chest and mediastinic pathologies Reactivity of the respiratory tract (asthma, bronchospasm and dispnea). Gastrointestinal diseases The most commonly observed adverse events are gastrointestinal. After administration of flurbiprofen have been reported: nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematitis, ulcerative stomatitis, gastrointestinal hemorrhage and exacerbation of colitis and Crohn's disease. Less frequently gastritis, peptic ulcer, drilling and ulcer hemorrhage were observed. Pathologies of skin and subcutaneous tissue Skin disorders including rash, itching, hives, porpora and very rarely bollose dermatosis (including Stevens- Johnson Syndrome, Toxic Necrolysis Epidermal and Multiform Erythema). Kidney and urinary pathologies Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of kidney failure were reported. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

In view of the pharmaceutical form and its local use, it is rare that overdose situations may occur. Overdose symptoms may include nausea, vomiting and gastrointestinal irritation. The treatment of a possible overdose involves gastric lavender and, if necessary, correction of the plasma electrolytic framework. There is no specific antidote for flurbiprofen.

During the first and second trimester of pregnancy, flurbiprofen should not be administered if not in strictly necessary cases. The drug administered during pregnancy may delay the beginning of labor and increase its duration. Flurbiprofene administration is not recommended in nursing mothers.

Source: Farmadati